{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T06:34:21Z","timestamp":1769582061502,"version":"3.49.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1757-2215-7-48","type":"journal-article","created":{"date-parts":[[2014,5,7]],"date-time":"2014-05-07T07:02:44Z","timestamp":1399446164000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["The feasibility and clinical effects of dendritic cell-based immunotherapy targeting synthesized peptides for recurrent ovarian cancer"],"prefix":"10.1186","volume":"7","author":[{"given":"Masanori","family":"Kobayashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asako","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromi","family":"Izawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eri","family":"Yanagida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigetaka","family":"Shimodaira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshikazu","family":"Yonemitsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuta","family":"Shibamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noboru","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Nagaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"The DC-vaccine study group at the Japan Society of Innovative Cell Therapy (J-SICT)","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,5,7]]},"reference":[{"key":"256_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.20138","volume":"62","author":"R Siegel","year":"2012","unstructured":"Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin 2012, 62: 10\u201329. 10.3322\/caac.20138","journal-title":"CA Cancer J Clin"},{"issue":"Suppl 1","key":"256_CR2","doi-asserted-by":"publisher","first-page":"S161","DOI":"10.1016\/S0020-7292(06)60033-7","volume":"95","author":"AP Heintz","year":"2006","unstructured":"Heintz AP, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, Ngan HY, Pecorelli S, Beller U: Carcinoma of the ovary. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 2006,95(Suppl 1):S161-S192.","journal-title":"Int J Gynaecol Obstet"},{"key":"256_CR3","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1200\/JCO.20.5.1248","volume":"20","author":"RE Bristow","year":"2002","unstructured":"Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ: Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002, 20: 1248\u20131259. 10.1200\/JCO.20.5.1248","journal-title":"J Clin Oncol"},{"key":"256_CR4","doi-asserted-by":"publisher","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","volume":"21","author":"RF Ozols","year":"2003","unstructured":"Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R, Gynecologic Oncology Group: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage iii ovarian cancer: a gynecologic oncology group study. J Clin Oncol 2003, 21: 3194\u20133200. 10.1200\/JCO.2003.02.153","journal-title":"J Clin Oncol"},{"key":"256_CR5","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s11912-011-0199-3","volume":"13","author":"M Hall","year":"2011","unstructured":"Hall M, Rustin G: Recurrent ovarian cancer: when and how to treat. Curr Oncol Rep 2011, 13: 459\u2013471. 10.1007\/s11912-011-0199-3","journal-title":"Curr Oncol Rep"},{"key":"256_CR6","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/32588","volume":"392","author":"J Banchereau","year":"1998","unstructured":"Banchereau J, Steinman RM: Dendritic cells and the control of immunity. Nature 1998, 392: 245\u2013252. 10.1038\/32588","journal-title":"Nature"},{"key":"256_CR7","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/nm0196-52","volume":"2","author":"FJ Hsu","year":"1996","unstructured":"Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996, 2: 52\u201358. 10.1038\/nm0196-52","journal-title":"Nat Med"},{"key":"256_CR8","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s00262-011-1081-8","volume":"61","author":"CS Chu","year":"2012","unstructured":"Chu CS, Boyer J, Schullery DS, Gimotty PA, Gamerman V, Bender J, Levine BL, Coukos G, Rubin SC, Morgan MA, Vonderheide RH, June CH: Phase I\/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission. Cancer Immunol Immunother 2012, 61: 629\u2013641. 10.1007\/s00262-011-1081-8","journal-title":"Cancer Immunol Immunother"},{"key":"256_CR9","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s00262-011-1100-9","volume":"61","author":"OE Rahma","year":"2012","unstructured":"Rahma OE, Ashtar E, Czystowska M, Szajnik ME, Wieckowski E, Bernstein S, Herrin VE, Shams MA, Steinberg SM, Merino M, Gooding W, Visus C, Deleo AB, Wolf JK, Bell JG, Berzofsky JA, Whiteside TL, Khleif SN: A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients. Cancer Immunol Immunother 2012, 61: 373\u2013384. 10.1007\/s00262-011-1100-9","journal-title":"Cancer Immunol Immunother"},{"key":"256_CR10","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.ygyno.2005.07.019","volume":"99","author":"S Koido","year":"2005","unstructured":"Koido S, Nikrui N, Ohana M, Xia J, Tanaka Y, Liu C, Durfee JK, Lerner A, Gong J: Assessment of fusion cells from patient-derived ovarian carcinoma cells and dendritic cells as a vaccine for clinical use. Gynecol Oncol 2005, 99: 462\u2013471. 10.1016\/j.ygyno.2005.07.019","journal-title":"Gynecol Oncol"},{"key":"256_CR11","doi-asserted-by":"publisher","first-page":"5323","DOI":"10.1158\/1078-0432.CCR-09-0737","volume":"15","author":"MA Cheever","year":"2009","unstructured":"Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, Matrisian LM: The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009, 15: 5323\u20135337. 10.1158\/1078-0432.CCR-09-0737","journal-title":"Clin Cancer Res"},{"key":"256_CR12","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ygyno.2005.09.052","volume":"101","author":"B Hylander","year":"2006","unstructured":"Hylander B, Repasky E, Shrikant P, Intengan M, Beck A, Driscoll D, Singhal P, Lele S, Odunsi K: Expression of Wilms tumor gene (WT1) in epithelial ovarian cancer. Gynecol Oncol 2006, 101: 12\u201317. 10.1016\/j.ygyno.2005.09.052","journal-title":"Gynecol Oncol"},{"key":"256_CR13","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/modpathol.3800588","volume":"19","author":"S Nakatsuka","year":"2006","unstructured":"Nakatsuka S, Oji Y, Horiuchi T, Kanda T, Kitagawa M, Takeuchi T, Kawano K, Kuwae Y, Yamauchi A, Okumura M, Kitamura Y, Oka Y, Kawase I, Sugiyama H, Aozasa K: Immunohistochemical detection of WT1 protein in a variety of cancer cells. Mod Pathol 2006, 19: 804\u2013814.","journal-title":"Mod Pathol"},{"key":"256_CR14","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1177\/030089169708300301","volume":"83","author":"E Seregni","year":"1997","unstructured":"Seregni E, Botti C, Massaron S, Lombardo C, Capobianco A, Bogni A, Bombardieri E: Structure, function and gene expression of epithelial mucins. Tumori 1997, 83: 625\u2013632.","journal-title":"Tumori"},{"key":"256_CR15","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.prp.2010.03.006","volume":"206","author":"XN Fan","year":"2010","unstructured":"Fan XN, Karsten U, Goletz S, Cao Y: Reactivity of a humanized antibody (hPankoMab) towards a tumor-related MUC1 epitope (TA-MUC1) with various human carcinomas. Pathol Res Pract 2010, 206: 585\u2013589. 10.1016\/j.prp.2010.03.006","journal-title":"Pathol Res Pract"},{"key":"256_CR16","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.ygyno.2007.02.004","volume":"105","author":"L Wang","year":"2007","unstructured":"Wang L, Ma J, Liu F, Yu Q, Chu G, Perkins AC, Li Y: Expression of MUC1 in primary and metastatic human epithelial ovarian cancer and its therapeutic significance. Gynecol Oncol 2007, 105: 695\u2013702. 10.1016\/j.ygyno.2007.02.004","journal-title":"Gynecol Oncol"},{"key":"256_CR17","first-page":"1051","volume":"18","author":"EV H\u00f8gdall","year":"2007","unstructured":"H\u00f8gdall EV, Christensen L, H\u00f8gdall CK, Blaakaer J, Gayther S, Jacobs IJ, Christensen IJ, Kjaer SK: Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the \u2018MALOVA\u2019 ovarian cancer study. Oncol Rep 2007, 18: 1051\u20131059.","journal-title":"Oncol Rep"},{"key":"256_CR18","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/MPA.0b013e31822398c6","volume":"41","author":"Y Kimura","year":"2012","unstructured":"Kimura Y, Tsukada J, Tomoda T, Takahashi H, Imai K, Shimamura K, Sunamura M, Yonemitsu Y, Shimodaira S, Koido S, Homma S, Okamoto M: Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and\/or S-1 in patients with advanced pancreatic carcinoma. Pancreas 2012, 41: 195\u2013205. 10.1097\/MPA.0b013e31822398c6","journal-title":"Pancreas"},{"key":"256_CR19","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1007\/s11605-013-2286-2","volume":"17","author":"M Kobayashi","year":"2013","unstructured":"Kobayashi M, Sakabe T, Abe H, Tanii M, Takahashi H, Chiba A, Yanagida E, Shibamoto Y, Ogasawara M, Tsujitani S, Koido S, Nagai K, Shimodaira S, Okamoto M, Yonemitsu Y, Suzuki N, Nagaya M, DC-vaccine study group at the Japan Society of Innovative Cell Therapy (J-SICT): Dendritic cell-based immunotherapy targeting synthesized peptides for advanced biliary tract cancer. J Gastrointest Surg 2013, 17: 1609\u20131617. 10.1007\/s11605-013-2286-2","journal-title":"J Gastrointest Surg"},{"key":"256_CR20","first-page":"871","volume":"94","author":"T Thavaramara","year":"2011","unstructured":"Thavaramara T, Phaloprakarn C, Tangjitgamol S, Manusirivithaya S: Role of neutrophil to lymphocyte ratio as a prognostic indicator for epithelial ovarian cancer. J Med Assoc Thai 2011, 94: 871\u2013877.","journal-title":"J Med Assoc Thai"},{"key":"256_CR21","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1200\/JCO.2008.17.8400","volume":"27","author":"J Berek","year":"2009","unstructured":"Berek J, Taylor P, McGuire W, Smith LM, Schultes B, Nicodemus CF: Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer. J Clin Oncol 2009, 27: 418\u2013425.","journal-title":"J Clin Oncol"},{"key":"256_CR22","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1016\/S0140-6736(03)13718-X","volume":"361","author":"MK Parmar","year":"2003","unstructured":"Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, Wheeler S, Swart AM, Qian W, Torri V, Floriani I, Jayson G, Lamont A, Trop\u00e9 C, ICON and AGO Collaborators: Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4\/AGO-OVAR-2.2 trial. Lancet 2003, 361: 2099\u20132106.","journal-title":"Lancet"},{"key":"256_CR23","doi-asserted-by":"publisher","first-page":"4699","DOI":"10.1200\/JCO.2006.06.0913","volume":"24","author":"J Pfisterer","year":"2006","unstructured":"Pfisterer J, Plante M, Vergote I, du Bois A, Hirte H, Lacave AJ, Wagner U, St\u00e4hle A, Stuart G, Kimmig R, Olbricht S, Le T, Emerich J, Kuhn W, Bentley J, Jackisch C, L\u00fcck HJ, Rochon J, Zimmermann AH, Eisenhauer E, AGO-OVAR; NCIC CTG; EORTC GCG.: Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 2006, 24: 4699\u20134707. 10.1200\/JCO.2006.06.0913","journal-title":"J Clin Oncol"},{"key":"256_CR24","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1093\/jnci\/djq310","volume":"102","author":"A Hoos","year":"2010","unstructured":"Hoos A, Eggermont AM, Janetzki S, Hodi FS, Ibrahim R, Anderson A, Humphrey R, Blumenstein B, Old L, Wolchok J: Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 2010, 102: 1388\u20131397. 10.1093\/jnci\/djq310","journal-title":"J Natl Cancer Inst"},{"key":"256_CR25","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1007\/s12032-011-0019-5","volume":"29","author":"V Asher","year":"2012","unstructured":"Asher V, Lee J, Bali A: Preoperative serum albumin is an independent prognostic predictor of survival in ovarian cancer. Med Oncol 2012, 29: 2005\u20132009. 10.1007\/s12032-011-0019-5","journal-title":"Med Oncol"},{"key":"256_CR26","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1159\/000010258","volume":"49","author":"N Boran","year":"2000","unstructured":"Boran N, Kayik\u00e7io\u011flu F, Yalva\u00e7 S, Tulunay G, Ekinci U, K\u00f6se MF: Significance of serum and peritoneal fluid lactate dehydrogenase levels in ovarian cancer. Gynecol Obstet Invest 2000, 49: 272\u2013274. 10.1159\/000010258","journal-title":"Gynecol Obstet Invest"},{"key":"256_CR27","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1007\/BF00121214","volume":"14","author":"R Mart\u00ednez-Zaguil\u00e1n","year":"1996","unstructured":"Mart\u00ednez-Zaguil\u00e1n R, Seftor EA, Seftor RE, Chu YW, Gillies RJ, Hendrix MJ: Acidic pH enhances the invasive behavior of human melanoma cells. Clin Exp Metastasis 1996, 14: 176\u2013186. 10.1007\/BF00121214","journal-title":"Clin Exp Metastasis"},{"key":"256_CR28","first-page":"6517","volume":"54","author":"J Rozhin","year":"1994","unstructured":"Rozhin J, Sameni M, Ziegler G, Sloane BF: Pericellular pH affects distribution and secretion of cathepsin B in malignant cells. Cancer Res 1994, 54: 6517\u20136525.","journal-title":"Cancer Res"},{"key":"256_CR29","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1023\/A:1016792319207","volume":"4","author":"B Murray","year":"2001","unstructured":"Murray B, Wilson DJ: A study of metabolites as intermediate effectors in angiogenesis. Angiogenesis 2001, 4: 71\u201377. 10.1023\/A:1016792319207","journal-title":"Angiogenesis"},{"key":"256_CR30","doi-asserted-by":"publisher","first-page":"7311","DOI":"10.1128\/MCB.20.19.7311-7318.2000","volume":"20","author":"S Nemoto","year":"2000","unstructured":"Nemoto S, Takeda K, Yu ZX, Ferrans VJ, Finkel T: Role for mitochondrial oxidants as regulators of cellular metabolism. Mol Cell Biol 2000, 20: 7311\u20137318. 10.1128\/MCB.20.19.7311-7318.2000","journal-title":"Mol Cell Biol"},{"key":"256_CR31","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/j.1365-2613.2009.00641.x","volume":"90","author":"S Tazzyman","year":"2009","unstructured":"Tazzyman S, Lewis CE, Murdoch C: Neutrophils: key mediators of tumour angiogenesis. Int J Exp Pathol 2009, 90: 222\u2013231. 10.1111\/j.1365-2613.2009.00641.x","journal-title":"Int J Exp Pathol"},{"key":"256_CR32","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1007\/s00384-010-1052-0","volume":"25","author":"PR Ding","year":"2010","unstructured":"Ding PR, An X, Zhang RX, Fang YJ, Li LR, Chen G, Wu XJ, Lu ZH, Lin JZ, Kong LH, Wan DS, Pan ZZ: Elevated preoperative neutrophil to lymphocyte ratio predicts risk of recurrence following curative resection for stage IIA colon cancer. Int J Colorectal Dis 2010, 25: 1427\u20131433. 10.1007\/s00384-010-1052-0","journal-title":"Int J Colorectal Dis"},{"key":"256_CR33","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1073\/pnas.0712237105","volume":"105","author":"FS Hodi","year":"2008","unstructured":"Hodi FS, Butler M, Oble DA, Seiden MV, Haluska FG, Kruse A, Macrae S, Nelson M, Canning C, Lowy I, Korman A, Lautz D, Russell S, Jaklitsch MT, Ramaiya N, Chen TC, Neuberg D, Allison JP, Mihm MC, Dranoff G: Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A 2008, 105: 3005\u20133010. 10.1073\/pnas.0712237105","journal-title":"Proc Natl Acad Sci U S A"},{"key":"256_CR34","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1073\/pnas.0611533104","volume":"104","author":"J Hamanishi","year":"2007","unstructured":"Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, Higuchi T, Yagi H, Takakura K, Minato N, Honjo T, Fujii S: Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A 2007, 104: 3360\u20133365. 10.1073\/pnas.0611533104","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1757-2215-7-48.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T03:37:57Z","timestamp":1630553877000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/1757-2215-7-48"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,7]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["256"],"URL":"https:\/\/doi.org\/10.1186\/1757-2215-7-48","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,7]]},"assertion":[{"value":"25 January 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"48"}}